All In Biotech

NDA 218550 · Genentech INC

Rozlytrek

Entrectinib · Oral

Accelerated approvalPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Oct 20, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

38

6 Phase 3, 12 recruiting

FAERS reports

1,691

1,103 serious, 275 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 8, 2026.

ROZLYTREK is a kinase inhibitor indicated for the treatment of: Adult patients with ROS1- positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. ( 1.1 ) Adult and pediatric patients older than 1 month of age with solid tumors that: have a neurotrophic tyrosine receptor kinase ( NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. ( 1.2 ) 1.1 ROS1 -Positive Non-Small Cell Lung Cancer ROZLYTREK is indicated for the treatment of adult patients with ROS1- positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. 1.2 NTRK Gene Fusion-Positive Solid Tumors ROZLYTREK is indicated for the treatment of adult and pediatric patients older than 1 month of age with solid tumors that: have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response [see Clinical Studies (14.2) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in the...

Mechanism: Entrectinib is an inhibitor of the tropomyosin receptor tyrosine kinases (TRK) TRKA, TRKB, and TRKC (encoded by the neurotrophic tyrosine receptor kinase [ NTRK ] genes NTRK1, NTRK2, and NTRK3 , respectively), proto-oncogene tyrosine-protein kinase ROS1 (ROS1), and anaplastic lymphoma kinase (ALK) with IC 50 values of 0.1 to 2 nM. Entrectinib also inhibits JAK2 and TNK2 with IC 50 values > 5 nM. The major active metabolite of entrectinib, M5, showed similar in vitro activity against TRK, ROS1, and ALK. Fusion proteins that include TRK, ROS1, or ALK kinase domains can drive tumorigenic...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 20, 2023 Original approval · Type 3 - New Dosage Form · priority review Accelerated approvalOrphanLetterReview
1 products under this application
  • ROZLYTREK · ENTRECTINIB 50MG/PACKET · PELLETS, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Entrectinib" as an intervention, any sponsor and status, largest first.

All 38 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use173
  • dizziness157
  • death135
  • disease progression119
  • taste disorder74
  • no adverse event72
  • drug ineffective69
  • constipation68
  • blood creatinine increased66
  • fatigue64
  • diarrhoea63
  • renal impairment62

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20171
20181
201932
2020125
2021233
2022288
2023263
2024467
2025172
2026109

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Rozlytrek (Entrectinib)

2024 spending

$19.1M

Beneficiaries

239

1,135 claims

Per beneficiary

$79,818

$219.73 per unit

View as table
YearSpending
2020$5,000,980
2021$9,829,447
2022$12,257,995
2023$15,596,859
2024$19,076,487

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 20 on PubMed

Sponsor: Roche (Genentech)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.